US Edition
News from oncnursingnews.com
We’ve assigned a media bias rating of unknown to oncnursingnews.com. You can read more about our methodology here.
If you want to know if oncnursingnews.com is credible or reliable, look no further. We rank oncnursingnews.com as Unknown factuality. Find out more about our methodology here.
Information about oncnursingnews.com
Where is oncnursingnews.com located?oncnursingnews.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top oncnursingnews.com News
Cancer · United StatesThe HARMONi-A study is the first Phase III trial of an immunotherapy for EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS)With a median follow-up of 32.5 months,…See the Story
Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
83% Center coverage: 6 sources
United States · United States(MedPage Today) -- The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated...See the Story
Two Drugs Approved for NPM1-Mutated Leukemia
80% Center coverage: 5 sources
Cancer · United States(MedPage Today) -- The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer.
FDA granted the targeted agent an...See the Story
Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar
100% Center coverage: 1 sources
